What the buyer needs
AI summaryThis announcement solicits research opportunities through the BARDA DRIVe EZ-BAA, now identified as EZ-BAA-22-100-SOL-00003. It supersedes previous versions of the BARDA DRIVe EZ-BAA. Several Areas of Interest (AOI) have been opened or revised through amendments, including ReDIRECT, Lab at Home, Digital MCMs, Host-Directed Therapeutics, Healing Lungs, DRIVe Forward, Vaccines on Demand, ReBooT, Host-Based Diagnostics, REPAIR, and FASTx. Specific closing dates for certain AOIs have been updated, paused, or reopened. For instance, AOI #15: ReDIRECT has a new closing date of February 15, 2023, and AOI #21: Vaccines on Demand has been reopened.
Incumbent and award research
No incumbent history found for this requirement. The notice does not cite a current contract, and no earlier award from this buying office matches it.
Market context
Awards in the same category (Research and Development in Biotechnology (except Nanobiotechnology)). This is not this requirement's award history.
Recent similar awards: Department of Health and Human Services, NAICS 541714
| Vendor and award | Value | Ends |
|---|---|---|
| AMGEN USA INC75A50122C00065 · TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MA | $839.9M | Sep 29, 2032 |
| 4J THERAPEUTICS INC75A50124C00052 · THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEMONSTRATE THE VERSATILITY AND EFFICACY OF O | $63.1M | Mar 31, 2032 |
| BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL75A50124C00033 · THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFE | $122.5M | Mar 31, 2032 |
| SRI INTERNATIONAL75N93026F00002 · TO AWARD TASK ORDER C03 | $722.0K | Feb 19, 2032 |
| ADVANCED TECHNOLOGY INTERNATIONAL75A50123F61002 · OT TASK ORDER 2 | $129.1M | Jan 31, 2032 |
Top vendors in this category: Department of Health and Human Services, NAICS 541714, since Oct 1, 2024
1,152 contract awards in this NAICS over the period.
- 1. ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)$336.6M
- 2. AMGEN USA INC$215.9M
- 3. START2 GROUP, INC.$194.3M
- 4. SHIONOGI INC$156.1M
- 5. MAPP BIOPHARMACEUTICAL, INC.$133.1M
Source: USAspending.gov federal award data (U.S. federal public data). A contract is called the incumbent only when the notice or its documents cite it by number.
